Total Contract Value (TCV)
$10.2B
+double-digit YoY
Record quarterly TCV, broad-based across industries and geographies, with no mega deals.
TCS
Information Technology
09 Jan 2025
Tata Consultancy Services Ltd — Q3 FY25
TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%. The highlight was a record TCV of $10.2 billion, broad-based across industries and geographies, with BFSI contributing $3.2 billion. Management noted early signs of discretionary spending revival, particularly in BFSI and retail, and a shortening of deal cycles. AI/GenAI deal momentum continues, with agentic AI gaining traction. However, North America revenue declined 2.3% YoY, and headcount fell to 607,354. The BSNL contract is 70% complete and will taper from Q4. Management expects CY25 to be better than CY24, driven by improving demand and strong pipeline. Key risk: macro uncertainty from US trade policies could dampen discretionary recovery.
टीसीएस ने तीसरी तिमाही में 63,973 करोड़ रुपये की कमाई की, जो पिछले साल से 5.6% ज्यादा है। कंपनी का मुनाफा बढ़कर 24.5% हो गया। सबसे बड़ी खबर यह है कि उन्हें 10.2 अरब डॉलर के नए ऑर्डर मिले, जिसमें बैंकिंग और वित्त क्षेत्र से 3.2 अरब डॉलर शामिल हैं। कंपनी का कहना है कि ग्राहक अब ज्यादा खर्च करने लगे हैं, खासकर बैंकिंग और रिटेल में। एआई से जुड़े काम भी बढ़ रहे हैं। हालांकि, उत्तरी अमेरिका में कमाई 2.3% घटी और कर्मचारियों की संख्या 607,354 रह गई। बीएसएनएल का 70% काम पूरा हो चुका है। कंपनी को उम्मीद है कि अगला साल इस साल से बेहतर रहेगा, लेकिन अमेरिकी व्यापार नीतियों से जोखिम है।
Key Numbers
BFSI TCV
$3.2B
strong YoY
BFSI led TCV with $3.2 billion; all large BFSI accounts in North America contributed to growth.
Attrition (LTM)
13%
flat sequentially
Attrition stable at 13%; workforce at 607,354 with 35.3% women.
Deal Cycle (deals >$20M)
reduced by a few weeks
improved vs prior quarter
Deal cycle shortened for large deals, indicating faster decision-making by clients.
What Changed vs Last Quarter
NEW
BSNL revenue to taper from Q4 FY25 through Q2 FY26
The BSNL contract is 70% complete; revenue will start tapering in Q4 and may extend to Q2 FY26. Management expects to replace most of it via other opportunities.
NEW
CY25 to be better than CY24 for international business
Management expects stronger growth in CY25 vs CY24, driven by early discretionary recovery and strong deal pipeline, despite BSNL headwinds.
NEW
Increased campus hiring next year
Preparations underway to onboard a higher number of campus hires next fiscal year, signaling confidence in future demand.
UPDATED
Margin aspiration of 26% by Q4 FY25
Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering.
DROPPED
Life sciences headwinds to stabilize in Q3, return to growth in Q4
Client-specific headwinds in life sciences and healthcare are expected to stabilize in Q3 and return to growth in Q4.
DROPPED
BSNL deal peak revenue to continue for one more quarter, then taper
The BSNL transformational program is at peak revenue; expected to remain at similar levels for one more quarter before tapering.
DROPPED
Growth markets as long-term growth driver
TCS is investing significantly in India, APAC, Latin America, and Middle East & Africa as sustainable long-term growth drivers.
NEW RISK
Macro uncertainty from US trade policies
Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.
NEW RISK
North America revenue decline
North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.
NEW RISK
Life sciences and healthcare recovery uncertainty
Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain.
RISK GONE
Client-specific scope reductions in life sciences
A large life sciences client abruptly reduced scope, causing revenue decline. Recovery depends on client's future investment decisions.
RISK GONE
Prolonged weakness in telecom and manufacturing
Telecom and manufacturing verticals face structural headwinds; telecom due to CapEx caution, manufacturing due to labor and supply chain issues.
RISK GONE
Margin pressure from growth market investments
Growth markets have lower margins; scaling them may pressure overall margins until volumes improve.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q3 FY24
CHRO Milind Lakkad indicated that the company aims to hire close to 40,000 trainees in FY25, consistent with historical practice.
Mentioned in Q1 FY24, Q1 FY25, Q3 FY24
North America revenue declined 1.1% YoY and BFSI remained negative YoY, with management citing ongoing client uncertainty and delayed decision-making.
Mentioned in Q1 FY25, Q4 FY24
Management reiterated that FY25 will be better than FY24 in terms of revenue growth, but declined to provide specific numbers.
Mentioned in Q2 FY24, Q3 FY24
Headcount declined by 5,600 in Q3. CHRO said further decline would not be surprising, which could signal lower utilization or demand.
Mentioned in Q1 FY24, Q1 FY25
CFO Samir Seksaria reaffirmed commitment to the 26-28% operating margin band, with levers including productivity, utilization, and pricing.
Management Guidance
Margin aspiration of 26% by Q4 FY25
Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering.
Management guidance marginsBSNL revenue to taper from Q4 FY25 through Q2 FY26
The BSNL contract is 70% complete; revenue will start tapering in Q4 and may extend to Q2 FY26. Management expects to replace most of it via other opportunities.
Management guidance revenueCY25 to be better than CY24 for international business
Management expects stronger growth in CY25 vs CY24, driven by early discretionary recovery and strong deal pipeline, despite BSNL headwinds.
Management guidance growthIncreased campus hiring next year
Preparations underway to onboard a higher number of campus hires next fiscal year, signaling confidence in future demand.
Management guidance otherKey Risks
Macro uncertainty from US trade policies
Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.
high · analyst_questionBSNL revenue tapering impact
The BSNL contract tapering from Q4 could create a revenue gap; management is confident of replacement but execution risk remains.
medium · management_commentaryNorth America revenue decline
North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.
medium · data_observationLife sciences and healthcare recovery uncertainty
Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain.
medium · management_commentaryNotable Quotes
The highlight of the quarter was our exceptionally strong and broad-based TCV at $10.2 billion.
We are seeing early signs of revival in discretionary spend in BFSI and retail.
Agentic AI represents the next step of maturity in the exponentially evolving space of AI.
Frequently Asked Questions
What was TCS's revenue in Q3 FY25?
TCS reported revenue of ₹63,973 Cr in Q3 FY25, representing a +5.6% change compared to the same quarter last year.
What guidance did TCS management give for FY26?
Margin aspiration of 26% by Q4 FY25: Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering. BSNL revenue to taper from Q4 FY25 through Q2 FY26: The BSNL contract is 70% complete; revenue will start tapering in Q4 and may extend to Q2 FY26. Management expects to replace most of it via other opportunities. CY25 to be better than CY24 for international business: Management expects stronger growth in CY25 vs CY24, driven by early discretionary recovery and strong deal pipeline, despite BSNL headwinds. Increased campus hiring next year: Preparations underway to onboard a higher number of campus hires next fiscal year, signaling confidence in future demand.
What are the key risks for TCS in FY26?
Key risks include Macro uncertainty from US trade policies — Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.; BSNL revenue tapering impact — The BSNL contract tapering from Q4 could create a revenue gap; management is confident of replacement but execution risk remains.; North America revenue decline — North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.; Life sciences and healthcare recovery uncertainty — Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain..
Did TCS meet its previous quarter's guidance?
Of 3 tracked promises, management 0 met, 0 close, 3 missed.
Where can I read the full TCS Q3 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.